scholarly journals Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels

2021 ◽  
pp. IJE33
Author(s):  
Hiroshi Katoh ◽  
Sabine Kajita ◽  
Mitsuo Yokota ◽  
Norihiko Sengoku ◽  
Takafumi Sangai
Keyword(s):  
Adverse Effect ◽  
Papillary Thyroid Carcinoma ◽  
Carotid Artery ◽  
Thyroid Carcinoma ◽  
Jugular Vein ◽  
Locally Advanced ◽  
Papillary Thyroid ◽  
Surgical Morbidity ◽  
Modified Neck Dissection ◽  
Reduce Risk

We report a 65-year old female with advanced papillary thyroid carcinoma involving the critical vessels including common carotid artery (CCA). She initially refused surgery and lenvatinib (LEN) was used in neoadjuvant setting. Primary tumor effectively shrank by LEN without any critical adverse effect. Total thyroidectomy and modified neck dissection were curatively performed. Tumor invading into internal jugular vein exhibited remarkable response to LEN and was almost replaced with necrosis and fibrosis. CCA was surrounded by fibrosis but was smoothly dissected from tumor and preserved. The patient shows no sign of recurrence for 2 years after surgery at present. Neoadjuvant LEN treatment can be new option for locally advanced papillary thyroid carcinoma involving critical vessels, particularly CCA, to reduce risk of surgical morbidity.

scholarly journals Advanced papillary thyroid carcinoma requiring reconstruction of the carotid artery and internal jugular vein: a case report

2011 ◽  
Vol 21 (1) ◽  
pp. 91-95
Author(s):  
Go Omura ◽  
Masashi Sugasawa ◽  
Seiichi Yoshimoto ◽  
Satoko Matsumura ◽  
Fumihiko Takajo ◽  
...  
Keyword(s):  
Case Report ◽  
Papillary Thyroid Carcinoma ◽  
Carotid Artery ◽  
Thyroid Carcinoma ◽  
Internal Jugular Vein ◽  
Jugular Vein ◽  
Papillary Thyroid

Mammary Analogue Secretory Carcinoma of the Thyroid Mimicking Locally Advanced Papillary Thyroid Carcinoma: A Rare Case Report

2017 ◽  
Vol 26 (5) ◽  
pp. 459-463 ◽  
Author(s):  
Haihui Liao ◽  
Ashraf Khan ◽  
Patricia M. Miron ◽  
Kristine M. Cornejo
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Rare Case ◽  
Locally Advanced ◽  
Final Diagnosis ◽  
Needle Aspiration ◽  
Papillary Thyroid ◽  
Secretory Carcinoma ◽  
Mammary Analogue Secretory Carcinoma ◽  
Molecular Therapeutic

Mammary analogue secretory carcinoma (MASC) harboring ETV6 gene rearrangements was first described in the salivary gland with a relatively favorable prognosis and a possible molecular therapeutic target with pan-Trk inhibitors. Recently, primary MASC of the thyroid gland has been reported. We report a case of a 4.0 cm MASC arising from the left thyroid of a 58-year-old female with extrathyroidal extension. Initially, it was diagnosed by fine needle aspiration as suspicious for papillary thyroid carcinoma (PTC) and subsequently called a poorly differentiated carcinoma on resection. A final diagnosis of primary MASC of the thyroid was confirmed after an expanded immunohistochemical panel and identification of an ETV6 gene rearrangement by fluorescence in situ hybridization. Morphologically, the tumor was composed of solid, microcystic and focally papillary growth with dense fibrotic stroma and necrosis. Overlapping cytological features with PTC were identified, including foci of enlarged cells with irregular nuclear membranes/grooves. However, most of the cells contained prominent nucleoli with intraluminal and intracytoplasmic eosinophilic secretions. Immunohistochemically, the tumor cells were strongly positive for pancytokeratin, cytokeratin 7, PAX8, mammaglobin, and GCDFP-15, with rare staining for GATA3 and S100 and negative for TTF-1 and thyroglobulin. We report a rare case of a primary thyroid MASC, initially misdiagnosed as PTC. Pathologists should be aware of this entity and, given the similarities to PTC, have a high index of suspicion, prompting the addition of immunohistochemical and molecular studies. Furthermore, an accurate diagnosis is important because of the possible prognostic and treatment implications.

scholarly journals Coexistence of Histologically Confirmed Hashimoto’s Thyroiditis with Different Stages of Papillary Thyroid Carcinoma in a Consecutive Chinese Cohort

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Xiaoyun Liu ◽  
Lijun Zhu ◽  
Dai Cui ◽  
Zhixiao Wang ◽  
Huanhuan Chen ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Hashimoto’S Thyroiditis ◽  
Locally Advanced ◽  
Maximum Diameter ◽  
Hashimoto's Thyroiditis ◽  
Papillary Thyroid ◽  
Gender And Age ◽  
Chinese Cohort ◽  
Local Lymph Node

Purpose. To determine the relationship between Hashimoto’s thyroiditis (HT) and all stages of papillary thyroid carcinoma (PTC) with or without local lymph node metastasis (LNM).Methods. We conducted a retrospective study of thyroidectomies from 2008–2013 in First Affiliated Hospital of Nanjing Medical University. We categorized patients according to the presence of histopathologically proven HT. The prevalence of mPTC (maximum diameter ≤ 10 mm) and crPTC (clinical relevant PTC) and local LNM rates were compared.Results. We evaluated 6,432 consecutive thyroidectomies. In total, 1,328 specimens were confirmed as HT. The prevalence of PTC in this HT cohort was 43.8%, significantly higher than non-HT group. After adjustment of gender and age, the prevalence of PTC was still higher in HT group. HT was a risk factor for PTC in multivariate analysis with odds ratio 2.725 (95% CI, 2.390–3.109) (P<0.001). However, no correlation was found between HT and LNM of PTC.Conclusion. HT was associated with an increased prevalence of all stages of PTC, independent of tumor size, gender, and age. In contrast, locally advanced disease defined by LNM was unrelated to HT. These data suggest an association of HT with low risk PTC and a potential protective immunologic effect from further disease progression.

Sign in / Sign up

Export Citation Format

Share Document